Skip to main content

T-cell expression of CD91 – a marker of unresponsiveness to anti-TNF therapy in rheumatoid arthritis

Buy Article:

$51.00 plus tax (Refund Policy)


Eriksson C, Rantapää-Dahlqvist S, Sundqvist K-G. T-cell expression of CD91 – a marker of unresponsiveness to anti-TNF therapy in rheumatoid arthritis. APMIS 2010; 118: 837–45.

The aim of this study was to investigate the expression of thrombospondin-1 (TSP-1) and its receptors, lipoprotein receptor-related protein/cluster of differentiation (CD)91, calreticulin (CRT), and CD47, on T cells and monocytes from patients with rheumatoid arthritis (RA) treated with anti-tumor necrosis factor (TNF) therapy. The surface expression of CD91 and associated components on CD3- and CD14-positive cells was examined using flow cytometry in 12 patients with established RA before and after beginning therapy and compared with that of 9 healthy controls and 12 patients with early RA treated with conventional therapies. CD3-positive cells from anti-TNF non-responders showed significantly greater expression of CD91 expression than those from responders (p < 0.05) after 6 weeks and when all measurements were pooled (p < 0.001). CD91 expression on CD3-positive cells from non-responders to other therapies was at the same level as in healthy controls. In contrast, CD14-positive cells showed no differences in CD91 expression between patients and controls or between responders and non-responders to anti-TNF therapy. The expression of TSP-1, CRT, and CD47 showed no differences between responders and non-responders. The results suggest T-lymphocyte expression of CD91 to be a biomarker that signifies unresponsiveness to anti-TNF therapy in patients with RA and may be used to identify potential responders and non-responders.

Keywords: CD91; Rheumatoid arthritis; T cells; anti-TNF; infliximab

Document Type: Research Article


Affiliations: 1: Departments of Clinical Immunology 2: Public Health and Clinical Medicine, Rheumatology, University Hospital, Umeå 3: Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden

Publication date: November 1, 2010


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more